SCHEMBL14294673

SCHEMBL14294673

CCn1nc(-c2ccc(Br)cc2)c(-c2ccc(OC)cc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.47
▸ KMT2A Q03164 6/20 0.47
▸ CCNE1 P24864 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ RAB9A P51151 4/20 0.46
▸ MAPT P10636 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ RXFP1 Q9HBX9 2/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ PTGDR2 Q9Y5Y4 1/20 0.46
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ L3MBTL1 Q9Y468 3/20 0.43
▸ HTT P42858 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ AURKA O14965 1/20 0.42
▸ NPC1 O15118 3/20 0.41
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13510672 0.85 LMNA (0.49) MEN1KMT2ACCNE1CDK2RAB9A
SCHEMBL13510724 0.85 KDM4E (0.57) MEN1KMT2ACDK2RAB9AMAPT
SCHEMBL14298815 0.83 MEN1 (0.45) MEN1KMT2ACCNE1CDK2RAB9A
SCHEMBL14270981 0.82 SRC (0.43) MEN1KMT2ACCNE1CDK2RAB9A
SCHEMBL14294733 0.81 NR1H2 (0.54) MEN1KMT2ACCNE1CDK2RAB9A
SCHEMBL14294732 0.78 KDR (0.44) MEN1KMT2ARAB9ANPC1GAA
SCHEMBL14294658 0.78 KMT2A (0.44) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL13510673 0.76 PDE10A (0.52) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL177569 0.75 MEN1 (0.59) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL10072211 0.75 GABRA1 (0.43) MEN1KMT2ARAB9AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080038225-A1 TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2008-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080038225-A1 TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS PRSS1, SPINT2, CTSC MEN1 4318/4885KMT2A 2796/4885CCNE1 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback